Herrstedt, J., Roila, F., & ESMO Guidelines Working Group (2009). Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Annals of Oncology, 20(Suppl. 4), 156–158.doi: 10.1093/annonc/mdp160
To provide guidance to clinicians for the prevention and management of chemotherapy-induced nausea and vomiting in patients receiving cancer chemotherapy of varying emetogenic potential
The evidence-based process was not fully described. Specific research was not stated. Literature cited were the antiemetic resource center at www.mascc.org and the Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer 2004 consensus conference, cited in Annals of Oncology 2006, 17, 20–28.
Levels of evidence and grades of recommendation as used by the American Society of Clinical Oncology (ASCO) were applied to specific recommendations and considered by the authors and European Society for Medical Oncology (ESMO) faculty. This was approved by the ESMO guidelines working group.
This reference provides definitions of nausea and vomiting; relative emetogenic potential of oral and IV drugs; recommended drugs, dosing, and schedules for antiemetic drugs; and recommendations for management of nausea and vomiting based on emetogenic potential.
Specific regimens are outlined below. Stated level (I–V) and grade of evidence assessed are shown in parentheses.